Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37656059.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1700.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Trastuzumab deruxtecan (T-DXd) is reshaping the therapeutic landscape of HER2-positive tumors. A recent article reports on the preclinical activity of the combination of T-DXd plus adavosertib, WEE1 kinase inhibitor, which promises to expand the use of this antibody-drug conjugate in HER2-positive tumors with CCNE1 coamplification. See related article by DiPeri et al., p. 4385.
Medical subject headings
- Immunoconjugates
- Neoplasms
- Breast Neoplasms